1 asset in Lentigo Maligna Melanoma
Therapeutic assets addressing Lentigo Maligna Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Dinaciclib Lentigo Maligna Melanoma | National Cancer Institute (NCI) | P2 | CCC (53) |